Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

132 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy and safety of OBI-1, an antihaemophilic factor VIII (recombinant), porcine sequence, in subjects with acquired haemophilia A.
Kruse-Jarres R, St-Louis J, Greist A, Shapiro A, Smith H, Chowdary P, Drebes A, Gomperts E, Bourgeois C, Mo M, Novack A, Farin H, Ewenstein B. Kruse-Jarres R, et al. Among authors: ewenstein b. Haemophilia. 2015 Mar;21(2):162-170. doi: 10.1111/hae.12627. Epub 2015 Jan 27. Haemophilia. 2015. PMID: 25623166 Clinical Trial.
Clinical evaluation of an advanced category antihaemophilic factor prepared using a plasma/albumin-free method: pharmacokinetics, efficacy, and safety in previously treated patients with haemophilia A.
Tarantino MD, Collins PW, Hay CR, Shapiro AD, Gruppo RA, Berntorp E, Bray GL, Tonetta SA, Schroth PC, Retzios AD, Rogy SS, Sensel MG, Ewenstein BM; RAHF-PFM Clinical Study Group. Tarantino MD, et al. Among authors: ewenstein bm. Haemophilia. 2004 Sep;10(5):428-37. doi: 10.1111/j.1365-2516.2004.00932.x. Haemophilia. 2004. PMID: 15357767 Clinical Trial.
Hemophilia therapy innovation: development of an advanced category recombinant factor VIII by a plasma/albumin-free method. Proceedings of a Special Symposium at the XIXth Congress of the International Society on Thrombosis and Haemostasis, July 12-18, 2003, Birmingham, UK.
Ewenstein BM, Collins P, Tarantino MD, Negrier C, Blanchette V, Shapiro AD, Baker D, Spotts G, Sensel M, Yi SE, Gomperts ED. Ewenstein BM, et al. Semin Hematol. 2004 Jan;41(1 Suppl 2):1-16; discussion 16-8. doi: 10.1016/s0037-1963(04)00017-4. Semin Hematol. 2004. PMID: 15071785
Consensus recommendations for use of central venous access devices in haemophilia.
Ewenstein BM, Valentino LA, Journeycake JM, Tarantino MD, Shapiro AD, Blanchette VS, Hoots WK, Buchanan GR, Manco-Johnson MJ, Rivard GE, Miller KL, Geraghty S, Maahs JA, Stuart R, Dunham T, Navickis RJ. Ewenstein BM, et al. Haemophilia. 2004 Sep;10(5):629-48. doi: 10.1111/j.1365-2516.2004.00943.x. Haemophilia. 2004. PMID: 15357790 Review.
Plasma and albumin-free recombinant factor VIII: pharmacokinetics, efficacy and safety in previously treated pediatric patients.
Blanchette VS, Shapiro AD, Liesner RJ, Hernández Navarro F, Warrier I, Schroth PC, Spotts G, Ewenstein BM; rAHF-PFM Clinical Study Group. Blanchette VS, et al. Among authors: ewenstein bm. J Thromb Haemost. 2008 Aug;6(8):1319-26. doi: 10.1111/j.1538-7836.2008.03032.x. Epub 2008 May 22. J Thromb Haemost. 2008. PMID: 18503631 Free article.
132 results